EGFR mutations and gefitinib sensitivity in patients with metastatic non-squamous non-small cell lung cancer

19075 Background: Probability of clinical benefit from EGFR tyrosine kinase inhibitors in previously treated NSCLC pts is strongly associated with the presence of EGFR mutation. However, the experi...